Head to head
DT2216 against Navitoclax
The engineered answer to navitoclax's platelet problem, a degrader that hands the same protein to an E3 ligase platelets barely express. In its first human trial of 20 patients with solid tumours there was one dose-limiting toxicity, a grade 4 thrombocytopenia that resolved within 48 hours.
Column A
DT2216DT2216, VHL-recruiting PROTAC degrader of BCL-xL
The engineered answer to the navitoclax platelet problem: a degrader that hands BCL-xL to an E3 ligase platelets barely express. In the first human trial, 20 patients with solid tumours, only one dose-limiting toxicity occurred, a grade 4 thrombocytopenia that resolved within 48 hours.
Column B
NavitoclaxNavitoclax (ABT-263), oral BCL-2, BCL-xL and BCL-w inhibitor
The most-cited senolytic in mice, and the one that cannot be given to healthy people. In its first human trial, 29 of 55 patients with lymphoid cancers had grade 3 or 4 thrombocytopenia, because platelets survive on the same protein whose blockade kills senescent cells.
Side by side, on the facts we can check
| Attribute | DT2216 | Navitoclax |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Not approved. Investigational in oncology. First-in-human phase 1 completed with a recommended phase 2 dose of 0.4 mg/kg intravenously twice weekly; no ageing or senescence indication is registered. | Not approved for any indication, in any country. Investigational in oncology since 2006. No ageing or senescence indication is registered on ClinicalTrials.gov. |
| Half-life | Not reported | Not reported |
| Molecular weight | Not reported | Not reported |
| Mechanism | Established in human cell lines and mice, with the intended platelet sparing now supported by human phase 1 data: DT2216 binds BCL-xL and recruits the VHL E3 ubiquitin ligase, marking BCL-xL for proteasomal degradation. Because VHL is minimally expressed in platelets, the degradation is inefficient there. Senescent cells that depend on BCL-xL die when it is removed, which is the senolytic rationale, demonstrated in mice and not in people. In the human trial, BCL-xL degradation was confirmed in peripheral leukocytes at the top dose. | Established in human cells and in mice: navitoclax is a BH3 mimetic that occupies the binding groove of BCL-2, BCL-xL and BCL-w, freeing pro-apoptotic BAX and BAK and triggering apoptosis in cells that depend on those proteins. In mice, that dependency is what makes senescent cells selectively vulnerable. In humans, the same dependency in platelets produces thrombocytopenia, verified in the oncology dose-escalation data. The senolytic selectivity demonstrated in mice has never been demonstrated in a person. |
| Human studies cited | 4 | 4 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between DT2216 and Navitoclax?
DT2216: The engineered answer to the navitoclax platelet problem: a degrader that hands BCL-xL to an E3 ligase platelets barely express. In the first human trial, 20 patients with solid tumours, only one dose-limiting toxicity occurred, a grade 4 thrombocytopenia that resolved within 48 hours. Navitoclax: The most-cited senolytic in mice, and the one that cannot be given to healthy people. In its first human trial, 29 of 55 patients with lymphoid cancers had grade 3 or 4 thrombocytopenia, because platelets survive on the same protein whose blockade kills senescent cells.
Which has stronger research evidence, DT2216 or Navitoclax?
This database does not grade compounds. It counts what was run in people: 4 of the 6 studies cited on the DT2216 profile were human work, against 4 of 7 for Navitoclax. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are DT2216 and Navitoclax FDA-approved?
DT2216: Not approved. Investigational in oncology. First-in-human phase 1 completed with a recommended phase 2 dose of 0.4 mg/kg intravenously twice weekly; no ageing or senescence indication is registered.. Navitoclax: Not approved for any indication, in any country. Investigational in oncology since 2006. No ageing or senescence indication is registered on ClinicalTrials.gov..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.